Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.3700
+0.0608 (19.66%)
At close: Apr 20, 2026, 4:00 PM EDT
0.3987
+0.0287 (7.76%)
Pre-market: Apr 21, 2026, 5:12 AM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$12,100
Profits / Employee
-$6,050,624
Market Cap
38.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Longeveron | 38 |
| Senti Biosciences | 34 |
| Kyntra Bio | 34 |
| Palatin Technologies | 29 |
| ABVC BioPharma | 19 |
| Tevogen Bio Holdings | 18 |
| BriaCell Therapeutics | 16 |
OTLK News
- 13 days ago - Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA - GlobeNewsWire
- 26 days ago - Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - GlobeNewsWire
- 27 days ago - Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire